Related Experiment Videos
Cause-specific mortality in women receiving hormone replacement therapy
C Schairer1, H O Adami, R Hoover
1Environmental Epidemiology Branch, National Cancer Institute, Rockville, MD 20892-7374, USA.
Epidemiology (Cambridge, Mass.)
|January 1, 1997
Summary
Menopausal hormone replacement therapy (HRT) was associated with reduced mortality in Swedish women. While potent estrogens without progestin increased endometrial cancer risk, HRT generally lowered risks for ischemic heart disease and cerebrovascular events.
Area of Science:
- Reproductive Endocrinology
- Epidemiology
- Public Health
Background:
- Menopausal hormone replacement therapy (HRT) is widely used for symptom management.
- Assessing the long-term mortality risks and benefits of HRT is crucial for clinical decision-making.
Purpose of the Study:
- To evaluate the association between menopausal estrogen therapy and all-cause and cause-specific mortality.
- To compare risks associated with different types of estrogen and progestin formulations.
Main Methods:
- A population-based cohort study of 23,346 Swedish women prescribed menopausal estrogens.
- Follow-up for an average of 8.6 years to assess mortality outcomes.
- Standardized mortality ratios (SMRs) were calculated and compared to the general population.
Main Results:
- Overall all-cause mortality was reduced (SMR=0.77) compared to the general population.
- Mortality from ischemic heart disease and cerebrovascular diseases was significantly lower across HRT groups.
- Potent estrogens without progestin were associated with a 40% increase in endometrial cancer mortality.
Conclusions:
- Menopausal estrogen therapy, particularly combined estrogen-progestin regimens, is associated with reduced mortality.
- Careful selection of HRT type is important, as potent estrogens without progestin may increase endometrial cancer risk.
- Both patient selection factors and biological effects likely contribute to the observed mortality reductions.